This stock split makes sense, given the rapid price gains and beefy stock price. Changing hands at $1,383 per share on April 29, some small investors may have to save up for a single O'Reilly share.

The S&P 500 and Nasdaq-100 indices are still significantly below their recent highs but are now firmly out of bear market territory. As of this writing, the S&P 500 is about 10% below its 2025 ...

With that in mind, it's probably not surprising that Wall Street is screaming to buy Nvidia stock hand over fist right now. But should you listen? Nine analysts have issued ratings on Nvidia in ...

With that in mind, it's probably not surprising that Wall Street is screaming to buy Nvidia stock hand over fist right now. But should you listen? Where to invest $1,000 right now? Our analyst ...

The U.S. stock market has been on a roller coaster in 2025. After a tumultuous start to the year, driven by President Donald Trump's aggressive trade policies, recent developments suggest that the ...

The world is changing. After decades of a steady relationship -- albeit occasionally testy -- between China and the United States, a massive trade war has erupted. Investors are scared about what ...

Stock market volatility can be very unsettling for investors, especially when major U.S. market indexes like the Nasdaq Composite (NASDAQINDEX: ^IXIC) plunge by more than 20% (and into bear ...

Moody's has a robust economic moat, and its growing data analytics brings stability to its business model. Capital One's merger with Discover could help it better compete with dominant players ...

Some of those opportunities look especially attractive. Here are three dividend stocks down 20% or more to buy hand over fist right now. Where to invest $1,000 right now? Our analyst team just ...

Wake up with Breakfast news in your inbox every market day. Sign Up For Free » Here's the stock to buy hand over fist in April for investors looking to gain fintech exposure in their portfolios.

Amgen saw no fewer than 10 of its medications post double-digit sales growth last year. AbbVie expects sales for Rinvoq and Skyrizi together to reach $31 billion as soon as 2027. Both ...